RMR Wealth Builders Trims Stake in Humana Inc. (NYSE:HUM)

RMR Wealth Builders reduced its position in shares of Humana Inc. (NYSE:HUM) by 2.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,023 shares of the insurance provider’s stock after selling 53 shares during the quarter. RMR Wealth Builders’ holdings in Humana were worth $513,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of HUM. Marshall Wace LLP increased its holdings in Humana by 118.9% during the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after purchasing an additional 774,085 shares during the period. International Assets Investment Management LLC increased its holdings in Humana by 261,025.1% during the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after purchasing an additional 738,701 shares during the period. FMR LLC increased its holdings in shares of Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the period. Baupost Group LLC MA purchased a new position in shares of Humana in the 2nd quarter valued at $156,933,000. Finally, Thrivent Financial for Lutherans increased its holdings in shares of Humana by 639.8% in the 2nd quarter. Thrivent Financial for Lutherans now owns 385,782 shares of the insurance provider’s stock valued at $144,147,000 after acquiring an additional 333,636 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

NYSE HUM opened at $269.70 on Friday. The stock has a 50-day simple moving average of $273.25 and a two-hundred day simple moving average of $310.94. The firm has a market capitalization of $32.47 billion, a P/E ratio of 23.89, a PEG ratio of 2.12 and a beta of 0.55. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $459.76. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, equities analysts forecast that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.31%. Humana’s dividend payout ratio is presently 31.36%.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.32% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HUM. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and lifted their price target for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Deutsche Bank Aktiengesellschaft cut their price target on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a report on Thursday, October 3rd. KeyCorp assumed coverage on Humana in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. TD Cowen raised their price objective on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Finally, Jefferies Financial Group cut Humana from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $519.00 to $253.00 in a research report on Monday, October 7th. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Humana presently has an average rating of “Hold” and an average price target of $302.00.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.